These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 1314160)
1. The influence of aldose reductase on the oxidative burst in diabetic neutrophils. Tebbs SE; Lumbwe CM; Tesfaye S; Gonzalez AM; Wilson RM Diabetes Res Clin Pract; 1992 Feb; 15(2):121-9. PubMed ID: 1314160 [TBL] [Abstract][Full Text] [Related]
2. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients. Ihm SH; Yoo HJ; Park SW; Park CJ Metabolism; 1997 Jun; 46(6):634-8. PubMed ID: 9186297 [TBL] [Abstract][Full Text] [Related]
3. The role of aldose reductase inhibition in diabetic neutrophil phagocytosis and killing. Tebbs SE; Gonzalez AM; Wilson RM Clin Exp Immunol; 1991 Jun; 84(3):482-7. PubMed ID: 1904327 [TBL] [Abstract][Full Text] [Related]
4. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Sato N; Kashima K; Uehara Y; Ohtani K; Shimizu H; Mori M Diabetes Care; 1997 Jun; 20(6):995-8. PubMed ID: 9167113 [TBL] [Abstract][Full Text] [Related]
5. No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients. Hamada Y; Hammon K; Raskin P J Diabetes Complications; 1992; 6(2):111-5. PubMed ID: 1611134 [TBL] [Abstract][Full Text] [Related]
6. Effects of glucose and SNK-860, an aldose reductase inhibitor, on the polyol pathway and chemiluminescence response of human neutrophils in vitro. Kawamura T; Suzuki K; Matsumae H; Sano T; Sakamoto N; Hotta N Diabet Med; 1995 May; 12(5):392-6. PubMed ID: 7648800 [TBL] [Abstract][Full Text] [Related]
7. Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus. Osar Z; Samanci T; Demirel GY; Damci T; Ilkova H Exp Diabesity Res; 2004; 5(2):155-62. PubMed ID: 15203886 [TBL] [Abstract][Full Text] [Related]
8. Neutrophil aldose reductase activity and its association with established diabetic microvascular complications. Dent MT; Tebbs SE; Gonzalez AM; Ward JD; Wilson RM Diabet Med; 1991 Jun; 8(5):439-42. PubMed ID: 1830528 [TBL] [Abstract][Full Text] [Related]
9. Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes. Dent MT; Veves A; Tebbs SE; Gonzalez AM; Malik RA; Boulton AJ; Ward JD; Wilson RM Diabet Med; 1991 Dec; 8(10):911-6. PubMed ID: 1838041 [TBL] [Abstract][Full Text] [Related]
10. Neutrophil sorbitol production impairs oxidative killing in diabetes. Wilson RM; Tomlinson DR; Reeves WG Diabet Med; 1987; 4(1):37-40. PubMed ID: 2951217 [TBL] [Abstract][Full Text] [Related]
11. Superoxide production by neutrophils from diabetics and normal subjects in response to glucose and galactose. Lin X; Candlish JK; Thai AC Exp Mol Pathol; 1993 Jun; 58(3):229-36. PubMed ID: 8390941 [TBL] [Abstract][Full Text] [Related]
12. Increased erythrocyte aldose reductase activity in type 1 diabetic patients. Hamada Y; Kito R; Raskin P Diabet Med; 1991 Apr; 8(3):226-31. PubMed ID: 1828737 [TBL] [Abstract][Full Text] [Related]
13. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats. Kashima K; Sato N; Sato K; Shimizu H; Mori M Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489 [TBL] [Abstract][Full Text] [Related]
14. Effect of insulin and statil on aldose reductase expression in diabetic rats. Ghahary A; Chakrabarti S; Sima AA; Murphy LJ Diabetes; 1991 Nov; 40(11):1391-6. PubMed ID: 1936600 [TBL] [Abstract][Full Text] [Related]
15. Reduced anterograde and retrograde accumulation of axonally transported phosphofructokinase in streptozotocin-diabetic rats: effects of insulin and the aldose reductase inhibitor 'Statil'. Willars GB; Calcutt NA; Tomlinson DR Diabetologia; 1987 Apr; 30(4):239-43. PubMed ID: 2439402 [TBL] [Abstract][Full Text] [Related]
16. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Boland OM; Blackwell CC; Clarke BF; Ewing DJ Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670 [TBL] [Abstract][Full Text] [Related]
17. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Hamada Y; Kitoh R; Raskin P Diabetes; 1991 Oct; 40(10):1233-40. PubMed ID: 1936586 [TBL] [Abstract][Full Text] [Related]
18. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients. Hamada Y; Nishimura C; Koh N; Sakakibara F; Nakamura J; Tanimoto T; Hotta N Diabetes Care; 1998 Jun; 21(6):1014-8. PubMed ID: 9614624 [TBL] [Abstract][Full Text] [Related]
19. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study. Ratliff DM; Vander Jagt DJ; Eaton RP; Vander Jagt DL J Clin Endocrinol Metab; 1996 Feb; 81(2):488-92. PubMed ID: 8636255 [TBL] [Abstract][Full Text] [Related]
20. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus. Hamada Y; Kitoh R; Raskin P Diabet Med; 1993; 10(1):33-8. PubMed ID: 8435985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]